^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

LYL331

i
Other names: LYL331, NY-ESO-1-targeted TCR therapy incorporating Gen-R
Associations
Trials
Company:
Lyell Immunopharma
Drug class:
TCR modulator, NY ESO 1 inhibitor
Related drugs:
Associations
Trials
2years
Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-RTM genetic reprogramming technology (SITC 2022)
Background Letetresgene autoleucel (lete-cel; GSK3377794) is a first-generation (1st gen) NY-ESO-1-specific T-cell receptor (TCR) therapy with demonstrated clinical activity in solid tumors. Conclusions In addition to supporting the hypothesis that genetic reprogramming with Gen-R technology can delay the onset of exhaustion and improve the long-term durable functions of LYL331, these data show that c-Jun overexpression can provide immediate benefits to the NY-ESO-1-specific TCR therapy during primary stimulation in vitro . Based on these promising pre-clinical data, LYL331 may have the potential to improve clinical responses in patients with solid tumor malignancies.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CTAG1B (Cancer/testis antigen 1B) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • JUN (Jun proto-oncogene)
|
letetresgene autoleucel (GSK3377794) • LYL331